Oncology Institute (NASDAQ:TOI – Get Free Report) and Fresenius Medical Care AG & Co. KGaA (NYSE:FMS – Get Free Report) are both healthcare companies, but which is the superior investment? We will compare the two businesses based on the strength of their analyst recommendations, institutional ownership, dividends, earnings, risk, valuation and profitability.
Volatility and Risk
Oncology Institute has a beta of 0.36, indicating that its share price is 64% less volatile than the S&P 500. Comparatively, Fresenius Medical Care AG & Co. KGaA has a beta of 0.78, indicating that its share price is 22% less volatile than the S&P 500.
Analyst Ratings
This is a breakdown of current recommendations for Oncology Institute and Fresenius Medical Care AG & Co. KGaA, as reported by MarketBeat.
| Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score | |
| Oncology Institute | 1 | 0 | 4 | 0 | 2.60 |
| Fresenius Medical Care AG & Co. KGaA | 5 | 6 | 0 | 0 | 1.55 |
Profitability
This table compares Oncology Institute and Fresenius Medical Care AG & Co. KGaA’s net margins, return on equity and return on assets.
| Net Margins | Return on Equity | Return on Assets | |
| Oncology Institute | -7.42% | N/A | -24.68% |
| Fresenius Medical Care AG & Co. KGaA | 4.88% | 8.90% | 4.05% |
Insider & Institutional Ownership
36.9% of Oncology Institute shares are held by institutional investors. Comparatively, 8.4% of Fresenius Medical Care AG & Co. KGaA shares are held by institutional investors. 4.4% of Oncology Institute shares are held by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock will outperform the market over the long term.
Valuation and Earnings
This table compares Oncology Institute and Fresenius Medical Care AG & Co. KGaA”s gross revenue, earnings per share (EPS) and valuation.
| Gross Revenue | Price/Sales Ratio | Net Income | Earnings Per Share | Price/Earnings Ratio | |
| Oncology Institute | $502.73 million | 0.96 | -$60.61 million | ($0.37) | -13.14 |
| Fresenius Medical Care AG & Co. KGaA | $22.20 billion | 0.62 | $1.11 billion | $1.90 | 13.51 |
Fresenius Medical Care AG & Co. KGaA has higher revenue and earnings than Oncology Institute. Oncology Institute is trading at a lower price-to-earnings ratio than Fresenius Medical Care AG & Co. KGaA, indicating that it is currently the more affordable of the two stocks.
Summary
Fresenius Medical Care AG & Co. KGaA beats Oncology Institute on 8 of the 14 factors compared between the two stocks.
About Oncology Institute
-logo-1200x675.png?v=20220303080937){kind=logo}
The Oncology Institute, Inc., an oncology company, provides various medical oncology services in the United States. The company operates through three segments: Dispensary, Patient Services, and Clinical Trials & Other. It offers physician services, in-house infusion and dispensary, clinical trial, radiation, outpatient blood product transfusion, and patient support services, as well as educational seminars, support groups, and counseling services. The company also provides managing clinical trials, palliative care programs, stem cell transplants services, and other care delivery models associated with non-community-based academic and tertiary care settings; and conducts clinical trials for a range of pharmaceutical and medical device companies. It serves adult and senior cancer patients. The company has a strategic collaboration with Healthly Forge to offer cancer care services to patients in Southern California. The Oncology Institute, Inc. was founded in 2007 and is headquartered in Cerritos, California.
About Fresenius Medical Care AG & Co. KGaA
Fresenius Medical Care AG provides dialysis and related services for individuals with renal diseases in Germany, North America, and internationally. The company offers dialysis treatment and related laboratory and diagnostic services through a network of outpatient dialysis clinics; materials, training, and patient support services comprising clinical monitoring, follow-up assistance, and arranging for delivery of the supplies to the patient's residence; and dialysis services under contract to hospitals in the United States for the hospitalized end-stage renal disease (ESRD) patients and for patients suffering from acute kidney failure. It also develops, manufactures, and distributes various health care products, including polysulfone dialyzers, hemodialysis machines, peritoneal dialysis cyclers, peritoneal dialysis solutions, hemodialysis concentrates, solutions and granulates, bloodlines, renal pharmaceuticals, systems for water treatment, and acute cardiopulmonary and apheresis products. In addition, the company develops, acquires, and in-licenses renal pharmaceuticals; offers renal medications and supplies to patients at homes or to dialysis clinics; and provides vascular, cardiovascular, endovascular specialty, vascular care ambulatory surgery center, and physician nephrology and cardiology services. The company sells its products to dialysis clinics, hospitals, and specialized treatment clinics directly, as well as through local sales forces, independent distributors, dealers, and sales agents. Fresenius Medical Care AG was incorporated in 1996 and is headquartered in Bad Homburg, Germany.
Receive News & Ratings for Oncology Institute Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Oncology Institute and related companies with MarketBeat.com's FREE daily email newsletter.
